...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >A Comparison of Pharmaceutical Product Performance of Albuterol Inhalers Available in the United States and Those Obtained in a Mexican Border Town
【24h】

A Comparison of Pharmaceutical Product Performance of Albuterol Inhalers Available in the United States and Those Obtained in a Mexican Border Town

机译：在美国和在墨西哥边境城镇获得的沙丁胺醇吸入器的药品性能比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: American residents travel to Mexico to purchase medications for a fraction of US cost and frequently without prescription requirements. A previous bioequivalence study found differences in lung function measures between 2 brands of Mexican-manufactured albuterol inhalers (both 100 ug/puff). An investigation of the pharmaceutical performance of different inhalers available may illuminate why different clinical results may be observed and offer insight to consumer and provider expectations of such products. Objective: The purpose of this study is to provide some reasonable expectations for a medical tourist who shops in Mexico for albuterol metered dose inhalers (MDIs) or for their health care providers by comparing pharmaceutical product performance of the consumer-available brands. Methods: Five different albuterol MDI products were purchased in Nogales, Mexico. The albuterol content was quantified through high-performance liquid chromatography. The inhalers were analyzed to determine the amount of the albuterol dose that can be considered respirable and compared with the findings from 2 US innovator products. Results: The mean respirable mass for each brand of albuterol MDI was compared with that of the other 4 brands and the 2 US innovator products using Student's t test. All evaluations showed significant differences (P < .05) except for 3 comparisons (Sacrusyt vs Assal, P = .89; Xeneric-S vs non-US Ventolin, P = .98; Victory vs US Proventil HFA, P = .06). Conclusion: Since pharmaceutical variability was found among the albuterol MDIs evaluated in this study, consumers and clinicians should appreciate possible differences in product performance of albuterol MDIs obtained in Mexico.
机译：背景：美国居民前往墨西哥购买药品的费用仅为美国的一小部分，而且经常没有处方要求。先前的生物等效性研究发现，墨西哥制造的2种品牌沙丁胺醇吸入器（均为100 ug /粉扑）之间在肺功能指标方面存在差异。对可用的不同吸入器的药物性能进行的调查可能会阐明为什么可以观察到不同的临床结果，并为消费者和提供者对此类产品的期望提供洞察力。目的：本研究的目的是通过比较消费者可利用品牌的药品性能，为在墨西哥购买沙丁胺醇剂量吸入器（MDI）的医疗游客或其医疗保健提供者提供一些合理的期望。方法：在墨西哥的Nogales购买了五种不同的沙丁胺醇MDI产品。沙丁胺醇含量通过高效液相色谱法定量。对吸入器进行了分析，以确定可以呼吸的沙丁胺醇剂量，并与2种美国创新产品的发现进行了比较。结果：使用学生t检验比较了每个品牌的沙丁胺醇MDI的平均呼吸质量与其他4个品牌和2种美国创新产品的平均呼吸质量。除3个比较（Sacrusyt与Assal，P = .89; Xeneric-S与非美国Ventolin，P = .98;胜利与US Proventil HFA，P = .06）外，所有评估均显示出显着差异（P <.05）。 。结论：由于在本研究评估的沙丁胺醇MDI中发现了药物变异性，因此，消费者和临床医生应意识到在墨西哥获得的沙丁胺醇MDI产品性能可能存在差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号